Abstract #1335P, Eisen, A et. Al., “CTC Biomarker Assessment To Aid Dosing Selection of E6201, A Potent MEK1 Inhibitor, For Treatment Of BRAF-Mutated Melanoma.”
HomeBiomarkers & DiagnosticsResourcesAbstract #1335P, Eisen, A et. Al., “CTC Biomarker Assessment To Aid Dosing Selection of E6201, A Potent MEK1 Inhibitor, For Treatment Of BRAF-Mutated Melanoma.”
Abstract #1335P, Eisen, A et. Al., “CTC Biomarker Assessment To Aid Dosing Selection of E6201, A Potent MEK1 Inhibitor, For Treatment Of BRAF-Mutated Melanoma.”